PM&R Meeting Abstracts

Official abstracts site for the AAPM&R Annual Assembly and the PM&R Journal.

MENU 
  • Home
  • Meetings Archive
    • AAPM&R Annual Assembly 2022
    • AAPM&R Annual Assembly 2021
    • AAPM&R Annual Assembly 2020
    • AAPM&R Annual Assembly 2019
  • Resources
  • Advanced Search

Application of Platelet Rich Plasma to Chronic Tibialis Anterior Pain: A Case Series Presentation

Catherine Jameson, DO (Resident Physician, Zucker School of Medicine At Hofstra/Northwell PM&R Program, Manhasset, NY, United States); Calvin R. Chen, DO; Steve Aydin, DO

Meeting: AAPM&R Annual Assembly 2019

Session Information

Date: Friday, November 15, 2019

Session Title: Spine and Pain Case and Research Report

Session Time: 12:30pm-2:00pm

Location: Research Hub - Kiosk 7

Disclosures: Catherine Jameson, DO: Nothing to disclose

Objective: Platelet rich plasma (PRP) has become a main component of regenerative medicine and here we present an approach to treating chronic tibialis anterior (TA) tendon/muscle pain with PRP. Our goal is to determine the effectiveness of PRP in treating anterior ankle pain after failed traditional conventional therapeutic treatments.

Design: Retrospective Chart Review

Setting: Outpatient Interventional Pain Clinic

Participants: Ages 18 or greater, both genders, tibialis anterior tendon pain for > 6 months, failed conservative therapies with no long-term improvement, and had not undergone previous regenerative injections.

Interventions: Ultrasound-guided PRP tibialis anterior tendon injection

Main Outcome Measures: Numeric Rating Scale (NRS) pre and post injection Opioid Dosage Reduction

Results: The average pain score at baseline was 8±1.5 on NRS scale. The average percent change in pain between baseline and 8 weeks post treatment was 36±23.2% reduction or improvement. There was a significant reduction or improvement in pain at 8 weeks post PRP treatment when compared with baseline, P=.008, according to the self-report percent change in pain. The average opioid reduction between baseline and 8 weeks post treatment was 17±21.2%. Three of the patients who were on opioid pain medications did not change the dosage of opioids after 8 weeks PRP treatment. No significant change in opioid reduction after 8 weeks post PRP treatment was shown in this study when compared with baseline, P=.063.

Conclusions: Platelet-rich plasma (PRP) has become an increasingly popular novel approach for physicians to treat chronic musculoskeletal pain. Our study demonstrated that its use in chronic tibialis anterior pain showed that 8 weeks post PRP treatment significantly improved chronic tibialis anterior pain. In addition, there was a difference in opioid dosages between at baseline and 8 weeks post-PRP treatment. Although not statistically significant, the study suggested a tendency of lower opioid pain medication dosages after 8 weeks post-PRP treatment.

Level of Evidence: Level IV

To cite this abstract in AMA style:

Jameson C, Chen CR, Aydin S. Application of Platelet Rich Plasma to Chronic Tibialis Anterior Pain: A Case Series Presentation [abstract]. PM R. 2019; 11(S2)(suppl 2). https://pmrjabstracts.org/abstract/application-of-platelet-rich-plasma-to-chronic-tibialis-anterior-pain-a-case-series-presentation/. Accessed June 17, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to AAPM&R Annual Assembly 2019

PM&R Meeting Abstracts - https://pmrjabstracts.org/abstract/application-of-platelet-rich-plasma-to-chronic-tibialis-anterior-pain-a-case-series-presentation/

Leading the Way. Baltimore, MD & Virtual. October 20-23, 2022. #aapmr22

PM&R Journal

View issues of PM&R on the Wiley Online Library »

American Academy of Physical Medicine and Rehabilitation

Visit the official site for the American Academy of Physical Medicine and Rehabilitation »

AAPM&R Annual Assembly

Visit the official site for the AAPM&R Annual Assembly »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
Wiley